WT1 and acute myeloid leukemia: Immunological responses were observed, and 71% of the patients were still in CR at a median follow‐up of almost 5 years.8 Results of two major studies using monocyte‐derived DCs loaded with LAAs for post‐remission treatment of AML patients have been reported: vaccination with DCs electroporated with mRNA encoding hTERT resulted in antigen‐specific T‐cell responses in 11/19 patients; RFS after a median observation time of 52 months was 58%.9 Within a phase II trial, an anti‐leukaemic response was detected in 13/30 patients vaccinated with DCs loaded with wilms tumor 1 (WT1) mRNA.